Conference
Immunoscore predicts significant differences in time to recurrence in stage I colon cancer patients
| العنوان: | Immunoscore predicts significant differences in time to recurrence in stage I colon cancer patients |
|---|---|
| المؤلفون: | Galon, J., Hermitte, F., Mlecnik, B., Marliot, F., Bifulco, C., Lugli, A., Nagtegaal, I., Hartmann, A., Van den Eynde, Marc, Roehrl, M., Ohashi, P., Zavadova, E., Torigoe, T., Patel, P., Wang, Y., Kawakami, Y., Marincola, F., Ascierto, P., Fox, B., Pagès, F., Congress European Society for Medical Oncology 2019 |
| المساهمون: | UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service d'hépato-gastro-entérologie, UCL - (SLuc) Service d'oncologie médicale |
| المصدر: | Annals of Oncology, Vol. 30, no.9, p. ix30 (2019) |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2019 |
| المجموعة: | DIAL@USL-B (Université Saint-Louis, Bruxelles) |
| مصطلحات موضوعية: | Oncology, Hematology |
| الوصف: | Immunoscore® is an in vitro diagnostic test that predicts the risk of relapse in patients with Colon Cancer (CC) by measuring the host immune response at the tumor site. It is an immune risk-assessment tool providing independent and superior prognostic value than traditional histopathological risk parameters, and is intended to be used as an adjunct to the TNM classification. Currently, Immunoscore plays a critical role to guide post-surgery decisions in stage II & III CC patients. In stage I, survival rates are high and adjuvant chemotherapy is not typically recommended. However, approximately 10% of stage I CC tumors will recur even after surgical resection. Methods A subgroup analysis was performed on the stage I patients (n = 451) from the Immunoscore international validation study (Pagès et al. The Lancet 2018). Patients were classified by Immunoscore based on pre-defined cutoffs, either in 5 (IS 0-4) or in 3 categories: IS Low (IS0-1), Intermediate (IS 2), High (IS 3-4). Time to recurrence (TTR) was compared between Immunoscore categories. Results Immunoscore Low, Intermediate and High were observed in 14%, 47% and 39% of the cohort, respectively. Immunoscore was positively and significantly correlated with TTR. When adjusting the model with Immunoscore, age, gender, T-stage sidedness and MSI, Immunoscore remained the sole significant parameter (stratified by participating center HRlow vs high=7.82; 95% CI 1.49 − 41.01; p = 0.015). In multivariate analysis, the variable with the most important relative contribution to the risk (Chi2) was Immunoscore. The robust correlation between Immunoscore classification and TTR was further corroborated by a separate analysis of the same cohort distributed into five IS categories. In MSS stage I patients, TTR rates at 5 years were 100%, 98.1%, 93.5%, 85.4%, 87.5% for IS4, IS3, IS2, IS1, IS0, respectively. Conclusions Immunoscore® is a robust prognostic indicator of the risk of recurrence in stage I CC. This risk assessment tool reliably identifies a ... |
| نوع الوثيقة: | conference object |
| اللغة: | English |
| تدمد: | 0923-7534 |
| Relation: | boreal:277951; http://hdl.handle.net/2078.1/277951; urn:ISSN:0923-7534 |
| DOI: | 10.1093/annonc/mdz421 |
| الاتاحة: | http://hdl.handle.net/2078.1/277951 https://doi.org/10.1093/annonc/mdz421 |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.656A71EB |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 09237534 |
|---|---|
| DOI: | 10.1093/annonc/mdz421 |